comparemela.com

Latest Breaking News On - Department of medicine at harvard medical school - Page 1 : comparemela.com

Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma

Treatment with the combination of isatuximab, carfilzomib, lenalidomide, and dexamethasone generated high rates of minimal residual disease negativity in patients with newly diagnosed, high-risk multiple myeloma, irrespective of transplant status.

Hamburg
Germany
Dana-farber-cancer-institute
Massachusetts
United-states
Eppendorf
Nordrhein-westfalen
Boston
Lisa-leypoldt
Department-of-medicine-at-harvard-medical-school
Bristol-myers-squibb
University-medical-center-hamburg

vimarsana © 2020. All Rights Reserved.